Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1909 1
1911 1
1925 1
1936 1
1939 1
1944 2
1945 2
1946 5
1947 3
1948 5
1949 7
1950 3
1951 10
1952 5
1953 8
1954 8
1955 8
1956 7
1957 11
1958 11
1959 8
1960 10
1961 15
1962 14
1963 14
1964 9
1965 14
1966 14
1967 10
1968 15
1969 19
1970 18
1971 22
1972 12
1973 32
1974 23
1975 21
1976 25
1977 19
1978 45
1979 48
1980 47
1981 31
1982 42
1983 26
1984 45
1985 42
1986 34
1987 44
1988 55
1989 34
1990 49
1991 49
1992 62
1993 61
1994 54
1995 59
1996 65
1997 64
1998 45
1999 47
2000 55
2001 73
2002 68
2003 46
2004 51
2005 51
2006 84
2007 72
2008 92
2009 86
2010 92
2011 96
2012 93
2013 95
2014 84
2015 88
2016 72
2017 118
2018 111
2019 121
2020 112
2021 145
2022 120
2023 112
2024 116
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,475 results

Results by year

Filters applied: . Clear all
Page 1
Bimekizumab versus Secukinumab in Plaque Psoriasis.
Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, Paul C, De Cuyper D, Vanvoorden V, Madden C, Cioffi C, Peterson L, Blauvelt A. Reich K, et al. Among authors: warren rb. N Engl J Med. 2021 Jul 8;385(2):142-152. doi: 10.1056/NEJMoa2102383. Epub 2021 Apr 23. N Engl J Med. 2021. PMID: 33891380 Clinical Trial.
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M. Reich K, et al. Among authors: warren rb. Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2. Lancet. 2021. PMID: 33549193 Clinical Trial.
An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).
Esmail A, Oelofse S, Lombard C, Perumal R, Mbuthini L, Goolam Mahomed A, Variava E, Black J, Oluboyo P, Gwentshu N, Ngam E, Ackerman T, Marais L, Mottay L, Meier S, Pooran A, Tomasicchio M, Te Riele J, Derendinger B, Ndjeka N, Maartens G, Warren R, Martinson N, Dheda K. Esmail A, et al. Among authors: warren r. Am J Respir Crit Care Med. 2022 May 15;205(10):1214-1227. doi: 10.1164/rccm.202107-1779OC. Am J Respir Crit Care Med. 2022. PMID: 35175905 Clinical Trial.
Introduction.
Warren RS, Nakakura EK. Warren RS, et al. Surg Oncol. 2007 Dec;16(4):235. doi: 10.1016/j.suronc.2007.11.002. Epub 2007 Nov 26. Surg Oncol. 2007. PMID: 18035535 No abstract available.
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
Thaci D, Piaserico S, Warren RB, Gupta AK, Cantrell W, Draelos Z, Foley P, Igarashi A, Langley RG, Asahina A, Young M, Falqués M, Pau-Charles I, Mendelsohn AM, Rozzo SJ, Reich K. Thaci D, et al. Among authors: warren rb. Br J Dermatol. 2021 Aug;185(2):323-334. doi: 10.1111/bjd.19866. Epub 2021 May 4. Br J Dermatol. 2021. PMID: 33544883 Clinical Trial.
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.
Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, Crépy MN, Stingeni L, Serra-Baldrich E, Baranowski K, Korn S, Kurvits M, Plohberger U, Strange Vest N, Schliemann S; trial investigators. Bissonnette R, et al. Among authors: warren rb. Lancet. 2024 Aug 3;404(10451):461-473. doi: 10.1016/S0140-6736(24)01027-4. Epub 2024 Jul 18. Lancet. 2024. PMID: 39033766 Clinical Trial.
Answer to March 2019 Photo Quiz.
West T, Warren RA, Chow SK. West T, et al. Among authors: warren ra. J Clin Microbiol. 2019 Feb 27;57(3):e00382-18. doi: 10.1128/JCM.00382-18. Print 2019 Mar. J Clin Microbiol. 2019. PMID: 30814302 Free PMC article. No abstract available.
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Ritchlin CT, Kavanaugh A, Merola JF, Schett G, Scher JU, Warren RB, Gottlieb AB, Assudani D, Bedford-Rice K, Coarse J, Ink B, McInnes IB. Ritchlin CT, et al. Among authors: warren rb. Lancet. 2020 Feb 8;395(10222):427-440. doi: 10.1016/S0140-6736(19)33161-7. Lancet. 2020. PMID: 32035552 Clinical Trial.
Pancreatic adenocarcinoma.
Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB 3rd, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW 2nd, Malafa MP, Muscarella P 2nd, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA; NCCN Pancreatic Adenocarcinoma. Tempero MA, et al. Among authors: warren rs. J Natl Compr Canc Netw. 2010 Sep;8(9):972-1017. doi: 10.6004/jnccn.2010.0073. J Natl Compr Canc Netw. 2010. PMID: 20876541 Free PMC article. No abstract available.
3,475 results